Several clinical trials employing peptide- or dendritic cell-based cancer vaccines targeting WT-1 are currently ongoing for the treatment of mesothelioma alone or in combination with immunotherapy (ClinicalTrials.gov ID: NCT04040231, NCT02649829, NCT05765084) (96, 97). The gene discussed is WT1; the disease is mesothelioma.